Clinical trials: Non-Alcoholic SteatoHepatitis (NASH)
Non Alcoholic Fatty Liver Disease
Genetics of Fatty Liver Disease in Children
This is a study to investigate genetic predisposition to hepatic steatosis and the expression of gluconeogenic and lipogenic genes in livers of obese children and adolescents.
- Trial name
- NCT01966627
- Testing
- ogtt, genotyping, abdominal and liver magnetic resonance imaging
- Where
- United States
- Volunteers
- 381 people
- Sponsor
- Yale University
Non-alcoholic Fatty Liver Disease
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and…
- Trial name
- ZENITH-1 (NCT07221227)
- Testing
- Efimosfermin alfa
- Where
- 91 sites in United States, Australia and 7 more
- Volunteers
- 1,200 people
- Sponsor
- GlaxoSmithKline
Menopause, Non Alcholic Fatty Liver Disease
MHT and Liver Function in Postmenopausal Women
This prospective study aims to evaluate the effects of menopausal hormone therapy (MHT) on liver function, lipid profiles, and hepatic steatosis in postmenopausal women.
- Conditions
- Menopause, Non Alcholic Fatty Liver Disease, Hepatic Steatosis
- Trial name
- NCT07103603
- Testing
- Menopausal hormone therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people
- Sponsor
- Ipek B. Ozcivit Erkan, MD
Non-alcoholic Fatty Liver Disease NAFLD
Clinical, Biochemical and Body Composition Analysis in Assessment of Steatosis in Non Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) includes a spectrum of liver disorders characterized by accumulation of hepatic fat in absence of significant alcohol consumption (<20 gm/day) and other causes of liver diseases.
- Trial name
- NCT04946786
- Testing
- Laboratory investigations, pelvi-abdominal US, fibroscan, and in body analysis
- Volunteers
- 80 people
- Sponsor
- Sohag University
T2DM With NAFLD
AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.
This is a phase I/IIa, randomized, single-blind, placebo-controlled, multiple-ascending dose study conducted at a single site. The study plans to include up to approximately 46 evaluable subjects with Type 2 Diabetes Mellitus…
- Trial name
- NCT02826525
- Testing
- AZD4076
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease
Optimizing the Beneficial Health Effects of Exercise for Diabetes: Focus on the Liver!
Due to the western lifestyle, correlated with a high calorie intake and low physical activity, obesity is becoming a major health problem. All over the world obesity reaches epidemic proportions.
- Conditions
- Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease, Obesity
- Trial name
- NCT01317576
- Testing
- Exercise intervention
- Where
- Netherlands
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Bram Brouwers
Type 2 Diabetes Mellitus (T2DM), Semaglutide
The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
To evaluate the effects of subcutaneous injection of semaglutide for 12 weeks on patients with type 2 diabetes mellitus (T2DM), compared with concurrent energy-restricted management, on glycemic control, weight loss, inflammatory…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Semaglutide, Caloric Restriction
- Trial name
- NCT07272343
- Testing
- semaglutide, caloric restriction
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Non-alcoholic Fatty Liver Disease
Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH
The primary objective of this study is the proof of mechanism and support of dose finding, together with the safety evaluation in patients with clinical evidence of NASH.
- Trial name
- NCT03166735
- Testing
- BI 1467335
- Where
- 44 sites in United States, Belgium and 7 more
- Volunteers
- 114 people
- Sponsor
- Boehringer Ingelheim
Kidney Transplant, Familial Hypercholesterolaemia
Cardiovascular Risk in Children With Chronic Conditions Study
Children living with chronic health conditions face a higher risk of developing cardiovascular diseases than their peers, largely due to the accelerated aging of the heart and blood vessels.
- Conditions
- Kidney Transplant, Familial Hypercholesterolaemia, Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM)
- Trial name
- CR3C (NCT07086989)
- Where
- 3 sites in Hungary
- Volunteers
- 300 people
- Sponsor
- Semmelweis University
NASH - Nonalcoholic Steatohepatitis, NAFLD
Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM
This is a randomized, placebo-controlled, four-arm, double-blind study. Subjects will be randomized (1:1:1:1) to receive either a daily oral placebo solution or a daily oral dose of 0.5 mg, 2.5 mg or 5.0 mg Foralumab Solution for…
- Conditions
- NASH - Nonalcoholic Steatohepatitis, NAFLD, T2DM (Type 2 Diabetes Mellitus)
- Trial name
- NCT03291249
- Testing
- Foralumab, Omeprazole 20mg
- Sponsor
- Tiziana Life Sciences LTD
Healthy
A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults
The current study is designed to evaluate the safety, tolerability and pharmacokinetics of PF-05221304 in healthy Japanese adult subjects following single and multiple dose administration.
- Trial name
- NCT03597217
- Testing
- PF-05221304
- Where
- Japan
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hepatic Fatty Acid Metabolism, Systemic Insulin Resistance
The Metabolic Effects of a High Fructose Versus a High Glucose Diet in Overweight Men
Dietary consumption of fructose has increased by nearly 50% since 1960. A high fructose diet (HFrD) results in greater visceral adiposity and systemic insulin resistance than a high glucose diet.
- Conditions
- Hepatic Fatty Acid Metabolism, Systemic Insulin Resistance, Oxidative Stress, Cardiovascular Status
- Trial name
- NCT01050140
- Testing
- high sugar diet
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Non-alcoholic Fatty Liver Disease
Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease
The purpose of this study is to evaluate the use of phlebotomy (blood taking)as a treatment for patients with non-alcoholic fatty liver disease.
- Trial name
- NCT00641524
- Testing
- Phlebotomy
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- University of Western Ontario, Canada
NASH/MASH, NAFLD/MASLD
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
- Trial name
- NCT06161571
- Testing
- Efruxifermin
- Where
- 211 sites in United States, Argentina and 11 more
- Volunteers
- 700 people
- Sponsor
- Akero Therapeutics, Inc
Hepatitis
Treating Nonalcoholic Steatohepatitis With Pioglitazone
Nonalcoholic steatohepatitis (NASH) is a common liver disease that resembles alcoholic hepatitis but occurs in persons who drink little or no alcohol.
- Trial name
- NCT00062764
- Testing
- Actos (Pioglitazone)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly
Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly).
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly, Nonalcoholic Fatty Liver (NAFL), Nonalcoholic Fatty Liver Disease (NAFLD)
- Trial name
- HEPACT (NCT07068191)
- Testing
- Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid), Ademetionine
- Where
- Russia
- Volunteers
- 90 people
- Sponsor
- Phenomen Pharma
Non-alcoholic Steatohepatitis (NASH)
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with NAFLD and NASH.
- Trial name
- NCT02927314
- Testing
- CF102
- Where
- 3 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Can-Fite BioPharma
NASH - Nonalcoholic Steatohepatitis, NASH
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis
This study will be a pilot study to evaluate the feasibility, safety and acceptability of Exercise and Liver FITness (EL-FIT), a mHealth exercise training program previously validated in patients with cirrhosis in patients with…
- Conditions
- NASH - Nonalcoholic Steatohepatitis, NASH, Exercise, Liver
- Trial name
- NCT06195943
- Testing
- Exercise Intervention with use of El-Fit App
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Milton S. Hershey Medical Center
Hepatocellular Carcinoma
Hepatocellular Carcinoma in Patients With a Cirrhosis Due to an Alcoholic or a Non Alcoholic Fatty Liver Disease
Global prevalence of Non Alcoholic Fatty Liver Diseases (NAFLD) ranges from 22% to 28%.The spectrum of these hepatic abnormalities extends from isolated steatosis to steatohepatitis (Non Alcoholic Steato-Hepatitis, NASH) and…
- Trial name
- CHALNA (NCT03307408)
- Testing
- blood collection
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
NASH - Nonalcoholic Steatohepatitis
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in cirrhotic subjects with biopsy-proven F4 compensated NASH.
- Trial name
- NCT05039450
- Testing
- EFX
- Where
- 49 sites in United States, Mexico and 1 more
- Volunteers
- 213 people
- Sponsor
- Akero Therapeutics, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.